Pharvaris
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Grafenauweg 8, Zug, Zug, 6300, Switzerla...Phone Number
+31 712036410Website
www.pharvaris.comRevenue
$104.2 MillionStock Symbol
PHVSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
2
1
About Pharvaris
Pharvaris is a clinical-stage biopharmaceutical company founded in 2015 that develops oral B2-receptor antagonists as therapeutic alternatives to injected treatments. The company focuses on creating novel small molecules for hereditary angioedema (HAE) and other B2-receptor-mediated conditions. Based in the Netherlands with additional operations in Switzerland and North America, Pharvaris specializes in pharmaceutical research and development for rare disorders. The company's innovative approach aims to improve treatment options and quality of life for patients with these conditions through more convenient oral medication delivery systems.Explore more
Pharvaris Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharvaris your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pharvaris, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Pharvaris is spiking on competitors!
Check if Pharvaris has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Pharvaris launches new products
Funding: Get notified immidiatlly once Pharvaris has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pharvaris recently announced quarterly report
Click to see if Pharvaris had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Pharvaris
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Pharvaris
Find more new buyers
Company Profile Activity
Activity Insights
Pharvaris is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pharvaris is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pharvaris.
Pharvaris financials insights
Gather financial insights about Pharvaris, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$18.3M
2019
Series B
$66M
2020
Series C
$80M
2025
Stock/Share Issuance
$201M
Pharvaris Tech Stack
A closer look at the technologies used by Pharvaris
See more technologies
Most Recent Scoops
Person-Based
Earnings, Stake & Stock Ownership, Finance, Financial Transactions
Person-Based
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations, Patient Experience
Person-Based
Medical Research
Pharvaris News & Media
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluatiPharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations from the Bradykinin Symposium 2026, which will take place from September 3-4, 2026, in Berlin, GermanPharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating rel
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pharvaris
Sign Up For FreeTo access detailed company insights
Pharvaris is a clinical-stage biopharmaceutical company founded in 2015 that develops oral B2-receptor antagonists as therapeutic alternatives to injected treatments. The company focuses on creating novel small molecules for hereditary angioedema (HAE) and other B2-receptor-mediated conditions. Based in the Netherlands with additional operations in... Read More
